Dyadic International (NASDAQ:DYAI) Stock Price Passes Below Fifty Day Moving Average – Time to Sell?

Dyadic International Inc. (NASDAQ:DYAI) shares crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.76 and traded as low as $0.7401. Dyadic International shares last traded at $0.8010, with a volume of 394,340 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Dyadic International presently has a consensus rating of “Hold” and an average target price of $3.00.

Dyadic International Stock Performance

The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. The stock has a market cap of $29.19 million, a price-to-earnings ratio of -3.48 and a beta of 1.17. The stock’s fifty day moving average is $0.76 and its 200-day moving average is $0.83.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The firm had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. On average, analysts forecast that Dyadic International Inc. will post 0.13 EPS for the current year.

Institutional Trading of Dyadic International

A number of institutional investors have recently modified their holdings of the stock. Marathon Capital Management acquired a new position in shares of Dyadic International in the 3rd quarter valued at approximately $41,000. Bank of America Corp DE increased its stake in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares during the last quarter. Landscape Capital Management L.L.C. bought a new position in Dyadic International in the third quarter valued at approximately $190,000. Geode Capital Management LLC raised its position in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares in the last quarter. Finally, Apis Capital Advisors LLC acquired a new position in Dyadic International during the third quarter valued at approximately $1,817,000. 27.95% of the stock is currently owned by institutional investors.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.